Susquehanna International Group’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Susquehanna International Group’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,400	Closed	-$371K	–	13651
2023 Q4	$371K	Buy	+14,400	New	+$270K	﹤0.01%	9364
2023 Q1	–	Sell	-10,300	Closed	-$181K	–	13707
2022 Q4	$181K	Sell	10,300 -300	-3%	-$4.84K	﹤0.01%	10275
2022 Q3	$160K	Buy	+10,600	New	+$185K	﹤0.01%	11152
2022 Q1	–	Sell	-30,800	Closed	-$763K	–	14192
2021 Q4	$763K	Buy	+30,800	New	+$619K	﹤0.01%	8008

Other funds holding CALT

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

MTIC

Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

Susquehanna International Group's CALT Position: Q3 2024 in Review

Susquehanna International Group sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2024, closing a stake of 5,397 shares — an estimated $210K sold.

Susquehanna International Group first reported a position in CALT in Q4 2023 and held it in 3 quarters. The position peaked at $243K in Q4 2023. 5 funds tracked by Wall St. Rank hold CALT as of Q3 2024.

Susquehanna International Group reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2024 after selling out during the quarter.
Susquehanna International Group sold 5,397 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2024, an estimated $210K.
Susquehanna International Group first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2023 and held it in 3 quarters.
Susquehanna International Group's Calliditas Therapeutics AB American Depositary Shares position peaked at $243K in Q4 2023.
5 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.